Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus propofol/alfentanil sedation during esophageal interventions
NL-OMON35831Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dexmedetomidine, propofol and alfentanil in Barrett's esophagus and esophageal cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Oxygen saturation, Exhaled carbon dioxide and 8 more. Started Jul 2012; status: active, not recruiting.
02
Drugs
dexmedetomidinepropofolalfentanil
03
Conditions
Barrett's esophagusesophageal cancer
Beyond the preview
Go deeper on NL-OMON35831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35831.